ATE389400T1 - Cis-2,4,5- triphenyl-imidazoline und ihre verwendung bei der behandlung von tumoren - Google Patents
Cis-2,4,5- triphenyl-imidazoline und ihre verwendung bei der behandlung von tumorenInfo
- Publication number
- ATE389400T1 ATE389400T1 AT02804883T AT02804883T ATE389400T1 AT E389400 T1 ATE389400 T1 AT E389400T1 AT 02804883 T AT02804883 T AT 02804883T AT 02804883 T AT02804883 T AT 02804883T AT E389400 T1 ATE389400 T1 AT E389400T1
- Authority
- AT
- Austria
- Prior art keywords
- imidazoline
- triphenyl
- tumors
- cis
- treatment
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 abstract 1
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 abstract 1
- 230000001028 anti-proliverative effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/22—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/24—Radicals substituted by nitrogen atoms not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US34171401P | 2001-12-18 | 2001-12-18 | |
| US39087402P | 2002-06-21 | 2002-06-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE389400T1 true ATE389400T1 (de) | 2008-04-15 |
Family
ID=26992625
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02804883T ATE389400T1 (de) | 2001-12-18 | 2002-12-09 | Cis-2,4,5- triphenyl-imidazoline und ihre verwendung bei der behandlung von tumoren |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US6734302B2 (de) |
| EP (1) | EP1458380B1 (de) |
| JP (1) | JP4477351B2 (de) |
| KR (2) | KR20060096513A (de) |
| CN (1) | CN100486969C (de) |
| AT (1) | ATE389400T1 (de) |
| AU (1) | AU2002366278B2 (de) |
| BR (1) | BR0215157A (de) |
| CA (1) | CA2469187C (de) |
| DE (1) | DE60225719T2 (de) |
| ES (1) | ES2301717T3 (de) |
| MX (1) | MXPA04005906A (de) |
| PA (1) | PA8561901A1 (de) |
| PE (1) | PE20030895A1 (de) |
| PL (1) | PL370823A1 (de) |
| RU (1) | RU2305095C2 (de) |
| TW (1) | TW200301112A (de) |
| UY (1) | UY27585A1 (de) |
| WO (1) | WO2003051359A1 (de) |
Families Citing this family (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7375125B2 (en) * | 1999-08-04 | 2008-05-20 | Ore Pharmaceuticals, Inc. | Melanocortin-4 receptor binding compounds and methods of use thereof |
| US20040204410A1 (en) * | 2002-06-21 | 2004-10-14 | Norman Kong | CIS-imidazolines |
| US7132421B2 (en) | 2003-06-17 | 2006-11-07 | Hoffmann-La Roche Inc. | CIS-imidazoles |
| US7425638B2 (en) | 2003-06-17 | 2008-09-16 | Hoffmann-La Roche Inc. | Cis-imidazolines |
| CA2528096C (en) * | 2003-06-17 | 2011-09-13 | F. Hoffmann-La Roche Ag | Cis-imidazolines as mdm2 inhibitors |
| BRPI0411841A (pt) * | 2003-06-17 | 2006-08-08 | Hoffmann La Roche | cis-2,4,5-triaril-imidazolinas |
| MXPA06013246A (es) * | 2004-05-18 | 2007-02-08 | Hoffmann La Roche | Nuevas imidazolinas cis. |
| US7893278B2 (en) * | 2004-06-17 | 2011-02-22 | Hoffman-La Roche Inc. | CIS-imidazolines |
| GB0419481D0 (en) * | 2004-09-02 | 2004-10-06 | Cancer Rec Tech Ltd | Isoindolin-1-one derivatives |
| NZ553646A (en) | 2004-09-22 | 2010-07-30 | Janssen Pharmaceutica Nv | Inhibitors of the interaction between MDM2 and p53 |
| US7579368B2 (en) * | 2005-03-16 | 2009-08-25 | Hoffman-La Roche Inc. | Cis-imidazolines |
| EP2311814A1 (de) | 2005-12-01 | 2011-04-20 | F. Hoffmann-La Roche AG | 2,4,5-Triphenylimidazolinderivate als Inhibitoren der Wechselwirkung zwischen P53 und MDM2-Proteinen zur Verwendung als Antikrebsmittel |
| WO2007082805A1 (en) * | 2006-01-18 | 2007-07-26 | F. Hoffmann-La Roche Ag | Cis-4, 5-biaryl-2-heterocyclic-imidazolines as mdm2 inhibitors |
| JP5385125B2 (ja) | 2006-03-22 | 2014-01-08 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | ＭＤＭ２とｐ５３の間の相互作用の阻害剤 |
| AU2007228784B2 (en) | 2006-03-22 | 2012-03-08 | Janssen Pharmaceutica N.V. | Cyclic-alkylaminederivatives as inhibitors of the interaction between MDM2 and p53 |
| CN101595107A (zh) | 2006-06-30 | 2009-12-02 | 先灵公司 | 能提高p53活性的有取代哌啶及其用途 |
| US8470785B2 (en) | 2006-07-28 | 2013-06-25 | St. Jude Children's Research Hospital | Method for treating ocular cancer |
| US8614192B2 (en) | 2006-07-28 | 2013-12-24 | Leiden University Medical Center | Method for treating ocular cancer |
| KR20090090383A (ko) | 2006-12-14 | 2009-08-25 | 다이이찌 산쿄 가부시키가이샤 | 이미다조티아졸 유도체 |
| US7625895B2 (en) * | 2007-04-12 | 2009-12-01 | Hoffmann-Le Roche Inc. | Diphenyl-dihydro-imidazopyridinones |
| PA8792401A1 (es) | 2007-08-06 | 2009-03-31 | Janssen Pharmaceutica Nv | Fenilendiaminas |
| MX2010003868A (es) | 2007-10-09 | 2010-04-27 | Hoffmann La Roche | Cis-imidazolinas quirales. |
| EP2224961A1 (de) * | 2007-11-26 | 2010-09-08 | The Research Foundation of the State University of New York | Kleinmolekülige krebsbehandlungen, die nekrose in krebszellen verursachen, aber normale zellen nicht angreifen |
| EP2298778A4 (de) | 2008-06-12 | 2011-10-05 | Daiichi Sankyo Co Ltd | Imidazothiazolderivat mit 4,7-diazaspiro[2.5]octan-ringstruktur |
| GB0811643D0 (en) | 2008-06-25 | 2008-07-30 | Cancer Rec Tech Ltd | New therapeutic agents |
| SG173028A1 (en) | 2009-01-16 | 2011-08-29 | Daiichi Sankyo Co Ltd | Imidazothiazole derivative having proline ring structure |
| AU2010210178B2 (en) | 2009-02-04 | 2014-06-05 | Janssen Pharmaceutica Nv | Indole derivatives as anticancer agents |
| IN2012DN01693A (de) * | 2009-08-26 | 2015-06-05 | Novartis Ag | |
| EP2488028B1 (de) | 2009-10-14 | 2020-08-19 | Merck Sharp & Dohme Corp. | Substituierte piperidine zur erhöhung der p53-aktivität und ihre verwendung |
| KR20120099462A (ko) | 2009-11-12 | 2012-09-10 | 더 리젠츠 오브 더 유니버시티 오브 미시건 | 스피로-옥신돌 ｍｄｍ2 길항제 |
| US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
| US10159669B2 (en) * | 2010-03-02 | 2018-12-25 | Ian H. Chan | Individual and combination of mdivi-1 and nutlin-3 for topical or intravitreal ophthalmic use |
| JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
| EP2621275B1 (de) | 2010-09-30 | 2018-03-28 | St. Jude Children's Research Hospital | Aryl-substituierte imidazole |
| FR2967072B1 (fr) | 2010-11-05 | 2013-03-29 | Univ Dundee | Procede pour ameliorer la production de virus et semences vaccinales influenza |
| MX2013005238A (es) | 2010-11-12 | 2013-09-02 | Univ Michigan | Antagonistas de mdm2 de espiro-oxindol. |
| CN103261229A (zh) | 2010-12-16 | 2013-08-21 | 罗切格利卡特公司 | 无岩藻糖基化cd20抗体与mdm2抑制剂的联合疗法 |
| DK2684880T3 (en) | 2011-03-10 | 2018-05-22 | Daiichi Sankyo Co Ltd | DISPIROPYRROLIDINE DERIVATIVES |
| BR112013028983A2 (pt) | 2011-05-11 | 2017-02-07 | Sanofi Sa | antagonistas mdm2 espiro-oxindol |
| CA2850166C (en) | 2011-09-27 | 2019-12-03 | Amgen Inc. | Heterocyclic compounds as mdm2 inhibitors for the treatment of cancer |
| WO2013054153A1 (en) | 2011-10-11 | 2013-04-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Nutlin compounds for use in he treatment of pulmonary hypertension |
| WO2013062923A1 (en) | 2011-10-28 | 2013-05-02 | Merck Sharp & Dohme Corp. | MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF |
| WO2013080141A1 (en) | 2011-11-29 | 2013-06-06 | Novartis Ag | Pyrazolopyrrolidine compounds |
| EP2793890B1 (de) | 2011-12-21 | 2016-09-07 | Merck Sharp & Dohme Corp. | Substituierte piperidine als hmd2-hemmer |
| US8815926B2 (en) * | 2012-01-26 | 2014-08-26 | Novartis Ag | Substituted pyrrolo[3,4-D]imidazoles for the treatment of MDM2/4 mediated diseases |
| CN104321325B (zh) | 2012-05-24 | 2016-11-16 | 诺华股份有限公司 | 吡咯并吡咯烷酮化合物 |
| TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
| US8846657B2 (en) * | 2012-12-20 | 2014-09-30 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as HDM2 inhibitors |
| WO2014115077A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Substituted purinone compounds |
| WO2014115080A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
| WO2014120748A1 (en) | 2013-01-30 | 2014-08-07 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as hdm2 inhibitors |
| US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
| WO2014134201A1 (en) | 2013-02-28 | 2014-09-04 | Amgen Inc. | A benzoic acid derivative mdm2 inhibitor for the treatment of cancer |
| EP2970237B1 (de) | 2013-03-14 | 2017-09-27 | Amgen Inc. | Cis-morpholinon und andere verbindungen als mdm2-inhibitoren zur behandlung von krebs |
| EP4438044A3 (de) | 2013-03-15 | 2024-12-04 | Board of Regents, The University of Texas System | Hemmung von lungenfibrose mit nutlin-3a und peptiden |
| US8975417B2 (en) | 2013-05-27 | 2015-03-10 | Novartis Ag | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |
| CN105209467B (zh) | 2013-05-27 | 2018-06-08 | 诺华股份有限公司 | 咪唑并吡咯烷酮衍生物及其在治疗疾病中的用途 |
| ES2650562T3 (es) | 2013-05-28 | 2018-01-19 | Novartis Ag | Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades |
| ES2656471T3 (es) | 2013-05-28 | 2018-02-27 | Novartis Ag | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de BET y su uso en el tratamiento de enfermedades |
| CN105358530A (zh) | 2013-06-10 | 2016-02-24 | 美国安进公司 | 制备mdm2抑制剂的方法及其结晶形式 |
| US9550796B2 (en) | 2013-11-21 | 2017-01-24 | Novartis Ag | Pyrrolopyrrolone derivatives and their use as BET inhibitors |
| US20170216286A1 (en) | 2014-01-28 | 2017-08-03 | Mayo Foundation For Medical Education And Research | Killing senescent cells and treating senescence-associated conditions using a src inhibitor and a flavonoid |
| US10328058B2 (en) | 2014-01-28 | 2019-06-25 | Mayo Foundation For Medical Education And Research | Treating atherosclerosis by removing senescent foam cell macrophages from atherosclerotic plaques |
| US20190269675A1 (en) | 2014-01-28 | 2019-09-05 | Buck Institute for Research and Aging | Treatment of parkinson's disease and other conditions caused or mediated by senescent astrocytes using small molecule senolytic agents |
| EP3099380B1 (de) | 2014-01-28 | 2021-08-11 | Buck Institute for Research on Aging | Verfahren und zusammensetzungen zum töten von seneszenten zellen und zur behandlung von erkrankungen und störungen im zusammenhang mit seneszenz |
| WO2015184383A1 (en) * | 2014-05-29 | 2015-12-03 | St. Jude Children's Research Hospital | Aryl-substituted imidazoles and methods of making and using same |
| GB201517217D0 (en) | 2015-09-29 | 2015-11-11 | Astex Therapeutics Ltd And Cancer Res Technology Ltd | Pharmaceutical compounds |
| GB201517216D0 (en) | 2015-09-29 | 2015-11-11 | Cancer Res Technology Ltd And Astex Therapeutics Ltd | Pharmaceutical compounds |
| AU2017246453A1 (en) | 2016-04-06 | 2018-11-08 | The Regents Of The University Of Michigan | Monofunctional intermediates for ligand-dependent target protein degradation |
| CN113788818A (zh) | 2016-04-06 | 2021-12-14 | 密执安大学评议会 | Mdm2蛋白质降解剂 |
| CN118436801A (zh) | 2016-05-20 | 2024-08-06 | 豪夫迈·罗氏有限公司 | Protac抗体缀合物及其使用方法 |
| GB201704965D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| GB201704966D0 (en) | 2017-03-28 | 2017-05-10 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| CN110088081A (zh) | 2017-06-16 | 2019-08-02 | 尤尼蒂生物技术公司 | 制备用于药物用途的对映纯顺式-咪唑啉化合物的合成方法 |
| CN112236162A (zh) | 2018-04-06 | 2021-01-15 | 昂科莱奇公司 | 用于裂解选择性癌细胞的组合物 |
| WO2019218904A1 (zh) * | 2018-05-18 | 2019-11-21 | 四川科伦博泰生物医药股份有限公司 | 非天然氨基酸类衍生物、其制备方法及用途 |
| EP3863720A1 (de) | 2018-10-08 | 2021-08-18 | The Regents Of The University Of Michigan | Kleinmolekülige mdm2-proteindegrader |
| MX2022011602A (es) | 2020-03-19 | 2023-01-04 | Kymera Therapeutics Inc | Degradadores de la proteína de homólogo de ratón de minuto 2 (mdm2) y usos de los mismos. |
| WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
| WO2023191513A1 (ko) * | 2022-03-29 | 2023-10-05 | 주식회사 퓨전바이오텍 | 당 결합된 이미다졸린 유도체 및 이의 용도 |
| WO2024240858A1 (en) | 2023-05-23 | 2024-11-28 | Valerio Therapeutics | Protac molecules directed against dna damage repair system and uses thereof |
| US11926597B1 (en) | 2023-11-08 | 2024-03-12 | King Faisal University | 4,5-bis(4-chlorophenyl)-1-hexyl-2-(3,4-dimethoxyphenyl)-1H-imidazole as an antimicrobial compound |
| US11981640B1 (en) | 2023-11-08 | 2024-05-14 | King Faisal University | 4,5-bis(4-chlorophenyl)-1-hexyl-2-(3-hydroxy-4-methoxyphenyl)-1H-imidazole as an antimicrobial compound |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL158178B (nl) * | 1974-07-12 | 1978-10-16 | Philips Nv | Werkwijze ter bereiding van insekticide preparaten die een pyrazolinederivaat bevatten, aldus verkregen gevormde preparaten, en werkwijze ter bereiding van pyrazolinederivaten met insekticide werking. |
| US5182268A (en) * | 1989-11-22 | 1993-01-26 | Marion Merrell Dow, Inc. | Pharmaceutical composition comprising daunorubicin potentiated with 2,4,5-tri (4-methoxyphenyl)-4,5-dihydroimidazole |
| WO1992003421A2 (en) | 1990-08-17 | 1992-03-05 | E.I. Du Pont De Nemours And Company | Arthropodicidal pyrazolines, pyrazolidines and hydrazines |
| DE19831987A1 (de) | 1998-07-16 | 2000-01-20 | Bayer Ag | Diphenylimidazoline |
| WO2000019994A1 (en) * | 1998-10-02 | 2000-04-13 | Board Of Trustees Of The University Of Illinois | Estrogen receptor ligands |
-
2002
- 2002-12-09 DE DE60225719T patent/DE60225719T2/de not_active Expired - Lifetime
- 2002-12-09 ES ES02804883T patent/ES2301717T3/es not_active Expired - Lifetime
- 2002-12-09 BR BR0215157-0A patent/BR0215157A/pt not_active IP Right Cessation
- 2002-12-09 EP EP02804883A patent/EP1458380B1/de not_active Expired - Lifetime
- 2002-12-09 JP JP2003552292A patent/JP4477351B2/ja not_active Expired - Lifetime
- 2002-12-09 AT AT02804883T patent/ATE389400T1/de active
- 2002-12-09 CN CNB028255402A patent/CN100486969C/zh not_active Expired - Fee Related
- 2002-12-09 KR KR1020067016636A patent/KR20060096513A/ko not_active Ceased
- 2002-12-09 WO PCT/EP2002/013904 patent/WO2003051359A1/en not_active Ceased
- 2002-12-09 CA CA2469187A patent/CA2469187C/en not_active Expired - Fee Related
- 2002-12-09 KR KR1020047009563A patent/KR100650966B1/ko not_active Expired - Fee Related
- 2002-12-09 RU RU2004122414/04A patent/RU2305095C2/ru not_active IP Right Cessation
- 2002-12-09 MX MXPA04005906A patent/MXPA04005906A/es active IP Right Grant
- 2002-12-09 PL PL02370823A patent/PL370823A1/xx not_active Application Discontinuation
- 2002-12-09 AU AU2002366278A patent/AU2002366278B2/en not_active Ceased
- 2002-12-11 US US10/316,695 patent/US6734302B2/en not_active Expired - Fee Related
- 2002-12-17 PA PA20028561901A patent/PA8561901A1/es unknown
- 2002-12-17 UY UY27585A patent/UY27585A1/es not_active Application Discontinuation
- 2002-12-18 TW TW091136528A patent/TW200301112A/zh unknown
-
2003
- 2003-01-06 PE PE2003000024A patent/PE20030895A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| UY27585A1 (es) | 2003-06-30 |
| BR0215157A (pt) | 2004-10-19 |
| EP1458380A1 (de) | 2004-09-22 |
| CN1606439A (zh) | 2005-04-13 |
| CA2469187A1 (en) | 2003-06-26 |
| JP4477351B2 (ja) | 2010-06-09 |
| ES2301717T3 (es) | 2008-07-01 |
| KR20040068277A (ko) | 2004-07-30 |
| PE20030895A1 (es) | 2003-10-25 |
| KR100650966B1 (ko) | 2006-11-30 |
| RU2305095C2 (ru) | 2007-08-27 |
| CA2469187C (en) | 2012-07-17 |
| TW200301112A (en) | 2003-07-01 |
| PA8561901A1 (es) | 2003-11-12 |
| DE60225719D1 (de) | 2008-04-30 |
| US6734302B2 (en) | 2004-05-11 |
| CN100486969C (zh) | 2009-05-13 |
| EP1458380B1 (de) | 2008-03-19 |
| DE60225719T2 (de) | 2009-04-23 |
| AU2002366278A1 (en) | 2003-06-30 |
| MXPA04005906A (es) | 2004-09-13 |
| KR20060096513A (ko) | 2006-09-11 |
| PL370823A1 (en) | 2005-05-30 |
| US20030153580A1 (en) | 2003-08-14 |
| RU2004122414A (ru) | 2005-06-27 |
| WO2003051359A1 (en) | 2003-06-26 |
| JP2005511766A (ja) | 2005-04-28 |
| AU2002366278B2 (en) | 2007-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE389400T1 (de) | Cis-2,4,5- triphenyl-imidazoline und ihre verwendung bei der behandlung von tumoren | |
| DE69835430D1 (de) | Sulfonamidderivate, ihre herstellung und verwendung | |
| HRP931531B1 (en) | Sulfonamides and their medical use | |
| NO962664D0 (no) | Forbindelser med veksthormonfrigjörende egenskaper | |
| DE60005560D1 (de) | Neuartiger p2x 7 rezeptor-antagonisten zur verwendung in der behandlung von entzündlichen, immuninduzierten erkrankungen oder erkrankungen des herz-kreislauf-systems | |
| ATE495187T1 (de) | Dalda-analoge und ihre verwendung | |
| TR200201505T2 (tr) | Terapötik maddeler olarak pirazolopirimidinler | |
| BR0215156A (pt) | Cis-imidazolinas como inibidores de mdm 2 | |
| TR200100918T2 (tr) | Aril ve heteroaril sübstitüentli üreler kullanılarak RAF kinazın inhibe edilmesi | |
| ATE318267T1 (de) | Einige alkylendiamin-substituierte heterocyclen | |
| DE69232323D1 (de) | Verwendung von Adenosinantagonisten zur Vorbeugung und Behandlung von Pankreatitis und Ulcera | |
| SE9703414D0 (sv) | New compounds | |
| ATE357438T1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
| TW200510387A (en) | Cis-2, 4, 5-triaryl-imidazolines | |
| ATE311389T1 (de) | Wirkstoffvorläufer von imidazopyridin-derivaten | |
| DE60235375D1 (de) | Platinkomplexe und deren verwendung in der therapie | |
| MXPA05013465A (es) | Cis-imidazolinas como inhibidores de mdm2. | |
| ATE201693T1 (de) | Hämoregulierende peptide | |
| EP1325918A4 (de) | Herzmuskelzellen-apoptose hemmstoffe und behandlung/vorbeugung von herzkrankheiten | |
| DE60034580D1 (de) | Peptid zur behandlung von nervenerkrankungen | |
| SE9902596D0 (sv) | Pharmaceutically active compounds | |
| RU2000122595A (ru) | Лекарственное средство для лечения пиелонефрита | |
| RU2002100743A (ru) | Средство, стимулирующее пролиферацию фибробластов | |
| DE69707690D1 (de) | Neue peptide und nootroper wirkstoff | |
| RU93045696A (ru) | Ингибиторы протеазы вируса иммунодефицита человека, полезные для лечения спида |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1458380 Country of ref document: EP |